NBIX Earnings Prediction
The chart below shows how NBIX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NBIX sees a -1.55% change in stock price 10 days leading up to the earnings, and a -3.37% change 10 days following the report. On the earnings day itself, the stock moves by +1.36%. This data can give you a slight idea of what to expect for the next quarter's release.
NBIX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
622.10M
24.72%
5.40%
Gross Margin
98.71%
0.98%
0.27%
Operating Margin
29.71%
4.95%
18.56%
Net Margin
20.86%
25.21%
89.46%
EPS
1.24
51.22%
96.83%
No Data Available
NBIX Earnings Analysis
Neurocrine Biosciences Inc Corporation (NBIX.O) Earnings Conference Call
Positive
Q3 Revenue Performance: 1. Strong Revenue Growth: Neurocrine reported $613 million in Q3 sales for INGREZZA, reflecting a 25% year-over-year growth at the midpoint of their revised guidance of $2.3 to $2.32 billion for the full year.
Pipeline Progress Update: 2. Pipeline Advancements: The company achieved proof-of-concept data in two out of three Phase II programs in psychiatry, significantly de-risking both NBI-’845 and NBI-’568 as they prepare for registrational studies in 2025.
Share Repurchase Plan Approval: 3. Share Repurchase Authorization: The Board of Directors approved a $300 million share repurchase plan, indicating confidence in the company's valuation and commitment to returning capital to shareholders.
Salesforce Expansion Strategy: 4. Salesforce Expansion: Neurocrine completed the expansion of its psychiatry and long-term care salesforce, which is expected to enhance market penetration and drive future sales growth for INGREZZA.
Tardive Dyskinesia Market Potential: 5. Market Opportunity in Tardive Dyskinesia: With an estimated 800,000 patients suffering from Tardive Dyskinesia and only 20% currently treated, Neurocrine sees significant growth potential in this market segment.
Negative
Clinical Trial Failure: 1. Failed Clinical Trial: The ERUDITE study of luvadaxistat for cognitive impairment in schizophrenia did not meet its primary endpoint, leading to the discontinuation of the program.
Pipeline Strategy Shift: 2. Pipeline Deprioritization: The decision to deprioritize Luvadaxistat and the NBI-104 program reflects a shift in focus away from certain assets, indicating potential weaknesses in the pipeline.
Competitive Landscape Concerns: 3. Increased Competition: Concerns were raised about the competitive landscape for INGREZZA, particularly with Teva's growing presence and the introduction of their XR formulation, which may impact market share.
Delayed Reimbursement Challenges: 4. Delayed Reimbursement Issues: For Crinecerfont, approximately 60% to 70% of CAH patients under commercial coverage may face delayed reimbursement for up to six months post-launch, potentially hindering initial uptake.
Patient Access Issues: 5. Market Access Challenges: The anticipated need for free goods programs during the reimbursement adjudication process for Crinecerfont suggests potential access challenges for patients, complicating the launch strategy.
NBIX FAQs
How does NBIX typically perform around its earnings report dates?
Is Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NBIX Earning Call Sentiment
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NBIX.O
-1.65%Positive
The earnings call reflects strong financial performance with 25% growth in INGREZZA sales and a raised guidance for 2024, signaling market confidence. The share repurchase plan indicates a commitment to shareholder returns, enhancing positive sentiment. Despite regulatory and competitive risks, optimistic guidance and strategic investments in R&D and pipeline development suggest robust future prospects. The Q&A section did not reveal significant negative concerns, maintaining an overall positive sentiment. The market is likely to react positively, expecting a stock price increase of 2% to 8% over the next two weeks.
